Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Retrospective, regional, multicenter study (including the Annecy-Genevois Hospital Center, the Chambéry Métropole Savoie Hospital Center, and the Grenoble University Hospital Center), comparing a cohort of patients treated with Cefazolin with a cohort of patients treated with Penicillin M
The use of Cefazolin for the treatment of infective endocarditis caused by Staphylococcus meti - S has become commonplace in France following the stockout of injectable Penicillin M, the reference treatment, which occurred during 2016.
There is currently no clinical data to prejudge the efficacy of Cefazolin in the context of high inoculum, such as in the treatment of infective endocarditis.
On the other hand, recent data have described a better tolerance profile for Cefazolin than for Penicillin M.
The objective of this study is to compare the efficacy and safety of Cefazolin with that of Penicillin M in the management of methicillin-susceptible staphylococcal endocarditis, through the analysis of two retrospective cohorts.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of the efficacy of Cefazolin in the treatment of Staphylococcus meti -S infective endocarditis, with that of Penicillin M, by observing the rate of death, relapse of infective endocarditis and occurence of embolic event. | The primary outcome is management failure, a composite outcome defined by the existence of at least one of the following:
| Day 10 (End of antibiotic treatment according to national recommendations |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of clinical and biological tolerance | Occurrence of adverse events such as: acute renal failure, coagulation disorder, cytolysis | 10 days (Occurrence of adverse events during the antibiotic treatment period) |
| Description of clinical predictive factors of failure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients included in the study are adults older than 18 years of age, who were treated between 01/01/2014 and 12/31/2018 for definite infective endocarditis according to Duke criteria. The infection must have been documented with Staphylococcus Meti -S, on native valve or device, and treated with Cefazolin or Penicillin M for at least 10 consecutive days.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mylène Maillet | CH Annecy Genevois | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Annecy Genevois | Metz-Tessy | 74374 | France |
Not provided
Not provided
Not provided
Not provided
Collection of clinical data in order to identify certain predictive factors of failure using directed acyclic graph. |
| 10 days (during the antibiotic treatment period) |
| Description of microbiological predictive factors of failure | Collection of microbiological data in order to identify certain predictive factors of failure using directed acyclic graph. | 10 days (during the antibiotic treatment period) |
| Description of ultrasound predictive factors of failure | Collection of ultrasound data in order to identify certain predictive factors of failure using directed acyclic graph. | 10 days (during the antibiotic treatment period) |
| ID | Term |
|---|---|
| D003141 | Communicable Diseases |
| D004696 | Endocarditis |
| ID | Term |
|---|---|
| D007239 | Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided